In the constantly evolving era of immunotherapy, blockade of the programmed cell death 1 (PD-1)/programmed cell death ligand-1 (PD-L1) immune checkpoint pathway represents one of the most promising strategies regarding reverting immune evasion in the cancer immunoediting process. Here, CD274 is linked to cancer.